Mesoblast Limited (NASDAQ:MESO) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Friday.

Other equities research analysts have also issued reports about the stock. CIBC began coverage on shares of Mesoblast Limited in a report on Thursday, August 31st. They set an “outperform” rating and a $16.00 price objective for the company. Maxim Group set a $14.00 price objective on shares of Mesoblast Limited and gave the company a “buy” rating in a report on Wednesday, August 16th. Zacks Investment Research raised shares of Mesoblast Limited from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 price objective on shares of Mesoblast Limited in a report on Wednesday, August 30th. Finally, BidaskClub lowered shares of Mesoblast Limited from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $13.64.

Shares of Mesoblast Limited (NASDAQ MESO) traded down 0.90% during midday trading on Friday, reaching $5.50. 15,657 shares of the company’s stock traded hands. The firm’s market capitalization is $467.19 million. The stock’s 50-day moving average price is $6.55 and its 200 day moving average price is $8.22. Mesoblast Limited has a one year low of $4.01 and a one year high of $12.50.

COPYRIGHT VIOLATION NOTICE: “Mesoblast Limited (MESO) Cut to Sell at ValuEngine” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/09/15/mesoblast-limited-meso-cut-to-sell-at-valuengine.html.

A hedge fund recently raised its stake in Mesoblast Limited stock. Princeton Capital Management Inc. increased its stake in Mesoblast Limited (NASDAQ:MESO) by 15.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 155,700 shares of the company’s stock after buying an additional 20,945 shares during the quarter. Princeton Capital Management Inc. owned about 0.20% of Mesoblast Limited worth $1,398,000 as of its most recent SEC filing. Institutional investors own 2.95% of the company’s stock.

About Mesoblast Limited

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Mesoblast Limited (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related companies with MarketBeat.com's FREE daily email newsletter.